<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619225</url>
  </required_header>
  <id_info>
    <org_study_id>20-001771</org_study_id>
    <nct_id>NCT04619225</nct_id>
  </id_info>
  <brief_title>Cardiac Output and Recovery Time</brief_title>
  <official_title>Correlation Between Cardiac Output and Recovery Time After Reversal of Rocuronium-Induced Blockade With Sugammadex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine the time it takes to reverse the effects of the&#xD;
      intraoperative medication given to relax the muscles and how this period of recovery&#xD;
      correlates with a function of the heart.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery time after administration of sugammadex and its correlation to cardiac output measure</measure>
    <time_frame>Up to 1 hour postoperative</time_frame>
    <description>Change in cardiac output measurement after reversal with sugammadex as compared to the time it takes to recover from the rocuronium-induced blockade.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of speed of recovery from neuromuscular blockade and age.</measure>
    <time_frame>Up to 1 hour postoperative</time_frame>
    <description>Change in the speed of recovery from neuromuscular blockade as compared to participant's age.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Residual Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group 1: Dominant Hand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and routine clinical monitor on non-dominant hand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Non-Dominant Hand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and routine clinical monitor on dominant hand</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TetraGraph</intervention_name>
    <description>FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.</description>
    <arm_group_label>Group 1: Dominant Hand</arm_group_label>
    <arm_group_label>Group 2: Non-Dominant Hand</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; or = 18 years old.&#xD;
&#xD;
          -  Patients willing to participate and provide an informed consent.&#xD;
&#xD;
          -  Patients undergoing an elective surgical procedure requiring administration of&#xD;
             rocuronium, and the use of a pulmonary artery catheter intraoperatively.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken&#xD;
             wrist with nerve damage, Dupuytren contracture.&#xD;
&#xD;
          -  Patients with systemic neuromuscular diseases such as myasthenia gravis.&#xD;
&#xD;
          -  Patients with significant organ dysfunction that can significantly affect&#xD;
             pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal&#xD;
             impairment or end-stage liver disease.&#xD;
&#xD;
          -  Patients having surgery that would involve prepping the arm or leg into the sterile&#xD;
             field.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.Ross Renew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>J. Ross Renew, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neuromuscular Blockade</keyword>
  <keyword>Tetragraph</keyword>
  <keyword>AMG</keyword>
  <keyword>EMG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

